Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis.
Psoriasis is an inflammatory disease characterized by the abnormal proliferation of skin cells, including dermal microvascular endothelial cells. Recently, chemokine-like factor 1 (CKLF1) was found to participate in the local inflammation and cell proliferation. To explore its role in the pathogenesis of psoriasis, the expression of both CKLF1 and its receptor (CCR4) was determined in the psoriatic lesions. Also, the effect of the C-terminal peptides (C19 and C27) of CKLF1 on the proliferation of human umbilical vein endothelial cells was studied in vitro. By immunohistochemistry and immunofluorescence, the expression of both CKLF1 and CCR4 was determined in the psoriatic lesions. The effect of C-terminal peptides on human umbilical vein endothelial cells (HUVECs) was studied in vitro by the evaluation of cell proliferation and apoptosis. The in vivo assessment was performed accordingly through the subcutaneous injection peptides on BALB/c mice. The results showed that, by immunohistochemistry, both CKLF1 and CCR4 were increasingly expressed in psoriatic lesions as compared to normal skins. Moreover, the primary umbilical vein endothelial cells exhibited higher proliferation ratio under the C19 or C27 stimulation, which was even enhanced by the addition of psoriatic sera or TNF-α. Furthermore, the enhancement of peptide simulation was accompanied with the activation of ERK1/2-MAPKs pathway. In addition, such effect of C19 and C27 was mirrored by the hyperproliferation of cutaneous microvessels in BALB/c mice that were subcutaneously injected with the two peptides. Therefore, we concluded that CKLF1 plays a role in the pathogenesis of psoriasis by promoting the proliferation of microvascular endothelial cells that possibly correlates with ERK1/2-MAPKs activation.
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yaqi
Y
Tan
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yixuan
Y
Wang
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Li
L
Li
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jinyu
J
Xia
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Shiguang
S
Peng
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yanling
Y
He
D000328:Adult; D000818:Animals; D015153:Blotting, Western; D049109:Cell Proliferation / Q000502:physiology*; D018925:Chemokines / Q000502:physiology*; D004730:Endothelium, Vascular / Q000166:cytology* / Q000503:physiopathology; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D066298:In Vitro Techniques; D020935:MAP Kinase Signaling System / Q000502:physiology; D062792:MARVEL Domain-Containing Proteins / Q000502:physiology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D055806:Microvessels / Q000166:cytology* / Q000503:physiopathology; D008875:Middle Aged; D011565:Psoriasis / Q000503:physiopathology*; D060888:Real-Time Polymerase Chain Reaction; D054398:Receptors, CCR4 / Q000502:physiology
C515354:CCR4 protein, human; C432676:CKLF protein, human; D018925:Chemokines; D062792:MARVEL Domain-Containing Proteins; D054398:Receptors, CCR4